SEC 13F Intelligence

Birchview Capital, LP / PTGX

Birchview Capital, LP’s Protagonist Therapeutics Inc Position

Does Birchview Capital, LP own Protagonist Therapeutics Inc (PTGX)? Yes35.0K shares worth $4M (+2.10% of its 13F portfolio) as of Q1 2026, down from 55.0K shares the prior filed quarter.

Position Value
$4M
Q1 2026
Shares
35.0K
% of Portfolio
+2.10%
Quarters Held
21
currently held

Position History PTGX

Reported value by quarter
Q1 ’21: $259,000Q1 ’21Q2 ’21: $449,000Q3 ’21: $673,000Q4 ’21: $1MQ4 ’21Q1 ’22: $900,000Q2 ’22: $301,000Q3 ’22: $320,000Q3 ’22Q4 ’22: $415Q1 ’23: $874Q2 ’23: $1MQ2 ’23Q3 ’23: $633,840Q4 ’23: $1MQ1 ’24: $1MQ1 ’24Q2 ’24: $2MQ3 ’24: $2MQ4 ’24: $2MQ4 ’24Q1 ’25: $2MQ2 ’25: $3MQ3 ’25: $3MQ3 ’25Q4 ’25: $5MQ1 ’26: $4Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202635.0K$4M+2.10%
Q4 202555.0K$5M+2.81%
Q3 202548.0K$3M+2.41%
Q2 202548.0K$3M+2.63%
Q1 202548.0K$2M+2.02%
Q4 202448.0K$2M+1.51%
Q3 202448.0K$2M+1.87%
Q2 202448.0K$2M+1.54%
Q1 202448.0K$1M+1.13%
Q4 202348.0K$1M+0.86%
Q3 202338.0K$633,840+0.54%
Q2 202338.0K$1M+0.79%
Q1 202338.0K$874+0.68%
Q4 202238.0K$415+0.29%
Q3 202238.0K$320,000+0.23%
Q2 202238.0K$301,000+0.22%
Q1 202238.0K$900,000+0.65%
Q4 202138.0K$1M+0.84%
Q3 202138.0K$673,000+0.46%
Q2 202110.0K$449,000+0.27%
Q1 202110.0K$259,000+0.15%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Birchview Capital, LP’s full portfolio or all institutional holders of PTGX.